Document Detail


Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man.
MedLine Citation:
PMID:  1091127     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lowering blood lipids has been invoked as a means of controlling future coronary events. In this prospective study, the effect of a lipid-reducing agent clofibrate (2 gm. daily) on extent of coronary artery disease was investigated. Forty patients, 32 having aortocoronary bypass, six having Vineberg operations, two having neither, were placed double-blind in placebo (24 patients) and clofibrate (16 patients) groups, and restudied by selective coronary angiography one year later. An additional 24 patients dropped from the study due to adverse drug reactions in eight. Each patient's right, left, anterior descending, and circumflex coronary arteries (with their branches) were separately rated according to degree of obstruction. The clofibrate group showed a significantly greater fall in triglyceride than did the placebo group (minus 13.7 per cent versus plus 2.3 per cent; p equal to 0.45). In the clofibrate group, 19 out of 64 coronary arteries (29.6 per cent) showed progressive coronary narrowing, not significantly different from the placebo group (24 out of 96 coronary arteries narrowed, 25 per cent; p equal to 0.26). No significant differences between drug groups emerged when the data were corrected for degree of fall of blood lipids, initial lipoprotein type, or effect in bypassed versus nonbypassed vessels (p always greater than 0.2). Regression of coronary artery disease was not seen. We conclude that clofibrate did not significantly influence the rate of progression of coronary artery disease in a one-year period.
Authors:
K Cohn; F J Sakai; M F Langston
Related Documents :
11481337 - Lipoprotein secretion and triglyceride stores in the heart.
20152247 - Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients wit...
11984217 - Wives of patients with acute myocardial infarction are at an increased risk of developi...
2685177 - Program on the surgical control of the hyperlipidemias (posch): design and methodology....
12962417 - Successful emergency aortic valve replacement following percutaneous cardiopulmonary su...
20024847 - Left ventricular dysfunction and nt-probnp levels in patients with one-vessel disease a...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American heart journal     Volume:  89     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  1975 May 
Date Detail:
Created Date:  1975-06-09     Completed Date:  1975-06-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  591-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arteriosclerosis / drug therapy,  mortality,  prevention & control
Cholesterol / blood
Clinical Trials as Topic
Clofibrate / adverse effects,  therapeutic use*
Coronary Artery Bypass
Coronary Disease / drug therapy,  mortality,  prevention & control*
Drug Evaluation
Humans
Lipids / blood*
Lipoproteins / blood
Middle Aged
Myocardial Revascularization
Placebos
Time Factors
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Lipids; 0/Lipoproteins; 0/Placebos; 0/Triglycerides; 57-88-5/Cholesterol; 637-07-0/Clofibrate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Age-related changes of cells involved in immune responses.
Next Document:  Ultrasound in the diagnosis of congenital heart disease.